NRIX expansion of BTK degrader backed by Roche partnership
NRIX said its BTK degrader is progressing in CLL, CSU and MS, while a Roche partnership expands indications and provides financial backing. The pipeline also includes STAT6 and IRAK4 degraders with multiple upcoming readouts.
The discussion pointed to robust clinical progress for the BTK degrader in CLL, CSU and MS, alongside a Roche partnership that expands indications and provides significant financial backing. Pipeline updates also included STAT6 and IRAK4 degraders, with multiple data readouts and key decisions expected.